IL1B and atherosclerosis: Results of the recent CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) have highlighted the importance of IL-1β for atherosclerosis, because patients with a history of atherosclerotic disease that were treated with an antibody against IL-1β experienced a significantly lower risk of having another cardiovascular event (40).